Biovest International spins off Cell Culture Company to focus on bioreactors and bioService solutions
![](/46/pdcnewsitem/03/87/76/CCC_logo.png)
Biovest International Inc. will spin off its instrument and contract manufacturing offerings into a single wholly-owned subsidiary named “Cell Culture Company, LLC.” Cell Culture Company will supply automated single-use perfusion bioreactor systems and custom mammalian cell and protein manufacturing services to the diagnostic, therapeutic, and animal healthcare industries.
Since the late 1990s, Biovest’s primary focus has been the commercialization of personalized immunotherapies. That work will continue under the Biovest name. “The spin-off of Cell Culture Company will ensure that our instrument and CMO customers will be better served through increased focus and investment,” says Cell Culture Company President Christiaan Engstrom.
For over 30 years, Biovest has been delivering innovative, cost effective, and scalable GMP custom mammalian cell and protein production and services solutions, from pre-clinical to commercial stages in mg to kg quantities. “It is our goal to be recognized as a preferred partner and industry leader in bioreactor technology and cell culture services,” says Mr. Engstrom.
Cell Culture Company delivers value through:
Cell Culture Company will remain located in the Minneapolis, Minnesota area in the same facility it has occupied since the 1980s. The 33,000 sq ft location is home to the corporate offices, bioreactor manufacturing operations, and a distribution center, as well as an FDA-compliant custom mammalian and protein production laboratory.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance